Analyzing GTX (GTXI) and SAGE Therapeutics (SAGE)

SAGE Therapeutics (NASDAQ: SAGE) and GTX (NASDAQ:GTXI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Earnings & Valuation

This table compares SAGE Therapeutics and GTX’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SAGE Therapeutics N/A N/A -$158.98 million ($6.87) -23.19
GTX N/A N/A -$17.72 million ($1.76) -8.24

SAGE Therapeutics is trading at a lower price-to-earnings ratio than GTX, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SAGE Therapeutics and GTX’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SAGE Therapeutics N/A -89.46% -78.94%
GTX N/A -125.79% -99.26%

Analyst Ratings

This is a breakdown of recent ratings and price targets for SAGE Therapeutics and GTX, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SAGE Therapeutics 1 1 12 0 2.79
GTX 0 0 2 0 3.00

SAGE Therapeutics currently has a consensus target price of $171.21, indicating a potential upside of 7.45%. GTX has a consensus target price of $17.00, indicating a potential upside of 17.16%. Given GTX’s stronger consensus rating and higher probable upside, analysts plainly believe GTX is more favorable than SAGE Therapeutics.

Insider and Institutional Ownership

95.5% of SAGE Therapeutics shares are held by institutional investors. Comparatively, 11.5% of GTX shares are held by institutional investors. 6.1% of SAGE Therapeutics shares are held by company insiders. Comparatively, 41.2% of GTX shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

SAGE Therapeutics has a beta of 2.98, meaning that its share price is 198% more volatile than the S&P 500. Comparatively, GTX has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500.

About SAGE Therapeutics

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

About GTX

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply